Scenarios that move BMY
Bristol-Myers Squibb Company Common Stock
Scenarios that move BMY: 14 analyses, 6 positive, 8 negative.
- · FDA expands ImmunityBio's Anktiva label for bladder cancer — ▼ · impact -35 · confidence low · horizon quarters
- · Syndax stock falls 16% as Phase II fibrosis study misses primary goal — ▲ · impact +14 · confidence low · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▼ · impact -25 · confidence high · horizon quarters
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +20 · confidence low · horizon quarters
- · HALO wins court order blocking Merck's European Keytruda SC — ▲ · impact +35 · confidence medium · horizon quarters
- · SRX Global SPV agrees to acquire CERo Therapeutics — ▼ · impact -21 · confidence medium · horizon weeks
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▼ · impact -45 · confidence low · horizon quarters
- · Genmab and AbbVie report positive epcoritamab lymphoma trial results — ▼ · impact -35 · confidence high · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▲ · impact +30 · confidence low · horizon quarters
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▼ · impact -17 · confidence low · horizon weeks
- · Zymeworks updates 2026 guidance after Theravance acquisition — ▼ · impact -25 · confidence low · horizon quarters
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -20 · confidence low · horizon quarters
- · CHMP backs CORT's Lifyorli combo for ovarian cancer — ▲ · impact +27 · confidence medium · horizon quarters
- · AstraZeneca's Etcamah fails late-stage study in first-line breast cancer — ▲ · impact +25 · confidence low · horizon quarters